Meibomian Gland Probing provides symptomatic relief in 91.4% of patients

Meibomian Gland Probing provides symptomatic relief in 91.4% of patients

More and more papers are coming out showing the benefit of Meibomian Gland Probing (MGP). This has been our findings as well. The paper below written by former colleagues at Harvard beat us to publication. Congratulations, Dr. Sutula. We need more papers looking at the benefit. I hope to see papers with before and after Lipiscans as well.
Sandra Lora Cremers, MD, FACS

 2017 Feb 17. doi: 10.1097/IOP.0000000000000876. [Epub ahead of print]

Dynamic Intraductal Meibomian Probing: A Modified Approach to the Treatment of Obstructive Meibomian Gland Dysfunction.

Author information

Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.



Obstructive meibomian gland dysfunction is a leading cause of ocular morbidity and its treatment remains a challenge. Meibomian gland probing was initially described in 2010. Here, the authors describe a modified technique, dynamic intraductal meibomian probing, which offers several advantages over the traditional approach including increased magnification, greater eyelid stabilization, enhanced anesthesia, and easier identification of gland orifices through the expression of meibum.


The authors conducted a retrospective chart review of 70 eyelids with treatment-resistant obstructive meibomian glanddysfunction undergoing dynamic intraductal meibomian probing between January 2013 and April 2015.


Immediately after the procedure, 91.4% of cases experienced symptomatic improvement, and no complications were noted.


Dynamic intraductal meibomian probing is an effective and safe treatment for obstructive meibomian gland dysfunction that is resistant to traditional therapies.
Shopping Cart